Whole-exome sequencing in two extreme phenotypes of response to VEGF-targeted therapies in patients with metastatic clear cell renal cell carcinoma

Andre P. Fay, Guillermo De Velasco, Thai H Ho, Eliezer M. Van Allen, Bradley Murray, Laurence Albiges, Sabina Signoretti, A. Ari Hakimi, Melissa L. Stanton, Joaquim Bellmunt, David F. McDermott, Michael B. Atkins, Levi A. Garraway, David J. Kwiatkowski, Toni K. Choueiri

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Advances in next-generation sequencing have provided a unique opportunity to understand the biology of disease and mechanisms of sensitivity or resistance to specific agents. Renal cell carcinoma (RCC) is a heterogeneous disease and highly variable clinical responses have been observed with vascular endothelial growth factor (VEGF)-targeted therapy (VEGF-TT). We hypothesized that whole-exome sequencing analysis might identify genotypes associated with extreme response or resistance to VEGF-TT in metastatic (mRCC). Patients with mRCC who had received first-line sunitinib or pazopanib and were in 2 extreme phenotypes of response were identified. Extreme responders (ERs) were defined as those with partial response or complete response for 3 or more years (n=13) and primary refractory patients (PRPs) were defined as those with progressive disease within the first 3 months of therapy (n=14). International Metastatic RCC Database Consortium prognostic scores were not significantly different between the groups (P=.67). Considering the genes known to be mutated in RCC at significant frequency, PBRM1 mutations were identified in 7 ERs (54%) versus 1 PRP (7%) (P=.01). In addition, mutations in TP53 (n=4) were found only in PRPs (P=.09). Our data suggest that mutations in some genes in RCC may impact response to VEGF-TT.

Original languageEnglish (US)
Pages (from-to)820-824
Number of pages5
JournalJNCCN Journal of the National Comprehensive Cancer Network
Volume14
Issue number7
StatePublished - Jul 1 2016

Fingerprint

Exome
Renal Cell Carcinoma
Vascular Endothelial Growth Factor A
Phenotype
Mutation
Mutation Rate
Therapeutics
Genes
Genotype
Databases
Clear-cell metastatic renal cell carcinoma

ASJC Scopus subject areas

  • Oncology

Cite this

Whole-exome sequencing in two extreme phenotypes of response to VEGF-targeted therapies in patients with metastatic clear cell renal cell carcinoma. / Fay, Andre P.; De Velasco, Guillermo; Ho, Thai H; Van Allen, Eliezer M.; Murray, Bradley; Albiges, Laurence; Signoretti, Sabina; Hakimi, A. Ari; Stanton, Melissa L.; Bellmunt, Joaquim; McDermott, David F.; Atkins, Michael B.; Garraway, Levi A.; Kwiatkowski, David J.; Choueiri, Toni K.

In: JNCCN Journal of the National Comprehensive Cancer Network, Vol. 14, No. 7, 01.07.2016, p. 820-824.

Research output: Contribution to journalArticle

Fay, AP, De Velasco, G, Ho, TH, Van Allen, EM, Murray, B, Albiges, L, Signoretti, S, Hakimi, AA, Stanton, ML, Bellmunt, J, McDermott, DF, Atkins, MB, Garraway, LA, Kwiatkowski, DJ & Choueiri, TK 2016, 'Whole-exome sequencing in two extreme phenotypes of response to VEGF-targeted therapies in patients with metastatic clear cell renal cell carcinoma', JNCCN Journal of the National Comprehensive Cancer Network, vol. 14, no. 7, pp. 820-824.
Fay, Andre P. ; De Velasco, Guillermo ; Ho, Thai H ; Van Allen, Eliezer M. ; Murray, Bradley ; Albiges, Laurence ; Signoretti, Sabina ; Hakimi, A. Ari ; Stanton, Melissa L. ; Bellmunt, Joaquim ; McDermott, David F. ; Atkins, Michael B. ; Garraway, Levi A. ; Kwiatkowski, David J. ; Choueiri, Toni K. / Whole-exome sequencing in two extreme phenotypes of response to VEGF-targeted therapies in patients with metastatic clear cell renal cell carcinoma. In: JNCCN Journal of the National Comprehensive Cancer Network. 2016 ; Vol. 14, No. 7. pp. 820-824.
@article{3f99661af2de469397916265bef9a695,
title = "Whole-exome sequencing in two extreme phenotypes of response to VEGF-targeted therapies in patients with metastatic clear cell renal cell carcinoma",
abstract = "Advances in next-generation sequencing have provided a unique opportunity to understand the biology of disease and mechanisms of sensitivity or resistance to specific agents. Renal cell carcinoma (RCC) is a heterogeneous disease and highly variable clinical responses have been observed with vascular endothelial growth factor (VEGF)-targeted therapy (VEGF-TT). We hypothesized that whole-exome sequencing analysis might identify genotypes associated with extreme response or resistance to VEGF-TT in metastatic (mRCC). Patients with mRCC who had received first-line sunitinib or pazopanib and were in 2 extreme phenotypes of response were identified. Extreme responders (ERs) were defined as those with partial response or complete response for 3 or more years (n=13) and primary refractory patients (PRPs) were defined as those with progressive disease within the first 3 months of therapy (n=14). International Metastatic RCC Database Consortium prognostic scores were not significantly different between the groups (P=.67). Considering the genes known to be mutated in RCC at significant frequency, PBRM1 mutations were identified in 7 ERs (54{\%}) versus 1 PRP (7{\%}) (P=.01). In addition, mutations in TP53 (n=4) were found only in PRPs (P=.09). Our data suggest that mutations in some genes in RCC may impact response to VEGF-TT.",
author = "Fay, {Andre P.} and {De Velasco}, Guillermo and Ho, {Thai H} and {Van Allen}, {Eliezer M.} and Bradley Murray and Laurence Albiges and Sabina Signoretti and Hakimi, {A. Ari} and Stanton, {Melissa L.} and Joaquim Bellmunt and McDermott, {David F.} and Atkins, {Michael B.} and Garraway, {Levi A.} and Kwiatkowski, {David J.} and Choueiri, {Toni K.}",
year = "2016",
month = "7",
day = "1",
language = "English (US)",
volume = "14",
pages = "820--824",
journal = "JNCCN Journal of the National Comprehensive Cancer Network",
issn = "1540-1405",
publisher = "Cold Spring Publishing LLC",
number = "7",

}

TY - JOUR

T1 - Whole-exome sequencing in two extreme phenotypes of response to VEGF-targeted therapies in patients with metastatic clear cell renal cell carcinoma

AU - Fay, Andre P.

AU - De Velasco, Guillermo

AU - Ho, Thai H

AU - Van Allen, Eliezer M.

AU - Murray, Bradley

AU - Albiges, Laurence

AU - Signoretti, Sabina

AU - Hakimi, A. Ari

AU - Stanton, Melissa L.

AU - Bellmunt, Joaquim

AU - McDermott, David F.

AU - Atkins, Michael B.

AU - Garraway, Levi A.

AU - Kwiatkowski, David J.

AU - Choueiri, Toni K.

PY - 2016/7/1

Y1 - 2016/7/1

N2 - Advances in next-generation sequencing have provided a unique opportunity to understand the biology of disease and mechanisms of sensitivity or resistance to specific agents. Renal cell carcinoma (RCC) is a heterogeneous disease and highly variable clinical responses have been observed with vascular endothelial growth factor (VEGF)-targeted therapy (VEGF-TT). We hypothesized that whole-exome sequencing analysis might identify genotypes associated with extreme response or resistance to VEGF-TT in metastatic (mRCC). Patients with mRCC who had received first-line sunitinib or pazopanib and were in 2 extreme phenotypes of response were identified. Extreme responders (ERs) were defined as those with partial response or complete response for 3 or more years (n=13) and primary refractory patients (PRPs) were defined as those with progressive disease within the first 3 months of therapy (n=14). International Metastatic RCC Database Consortium prognostic scores were not significantly different between the groups (P=.67). Considering the genes known to be mutated in RCC at significant frequency, PBRM1 mutations were identified in 7 ERs (54%) versus 1 PRP (7%) (P=.01). In addition, mutations in TP53 (n=4) were found only in PRPs (P=.09). Our data suggest that mutations in some genes in RCC may impact response to VEGF-TT.

AB - Advances in next-generation sequencing have provided a unique opportunity to understand the biology of disease and mechanisms of sensitivity or resistance to specific agents. Renal cell carcinoma (RCC) is a heterogeneous disease and highly variable clinical responses have been observed with vascular endothelial growth factor (VEGF)-targeted therapy (VEGF-TT). We hypothesized that whole-exome sequencing analysis might identify genotypes associated with extreme response or resistance to VEGF-TT in metastatic (mRCC). Patients with mRCC who had received first-line sunitinib or pazopanib and were in 2 extreme phenotypes of response were identified. Extreme responders (ERs) were defined as those with partial response or complete response for 3 or more years (n=13) and primary refractory patients (PRPs) were defined as those with progressive disease within the first 3 months of therapy (n=14). International Metastatic RCC Database Consortium prognostic scores were not significantly different between the groups (P=.67). Considering the genes known to be mutated in RCC at significant frequency, PBRM1 mutations were identified in 7 ERs (54%) versus 1 PRP (7%) (P=.01). In addition, mutations in TP53 (n=4) were found only in PRPs (P=.09). Our data suggest that mutations in some genes in RCC may impact response to VEGF-TT.

UR - http://www.scopus.com/inward/record.url?scp=84978910659&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84978910659&partnerID=8YFLogxK

M3 - Article

C2 - 27407122

AN - SCOPUS:84978910659

VL - 14

SP - 820

EP - 824

JO - JNCCN Journal of the National Comprehensive Cancer Network

JF - JNCCN Journal of the National Comprehensive Cancer Network

SN - 1540-1405

IS - 7

ER -